Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

217 ARTÍCULOS , VIENDO DEL 16 AL 30

Imaging Amyloid and Tau in the Retina: Current Research and Future Directions

Tang MY, Blazes MS, Lee CS.

J Neuroophthalmol. 2023 Jun 1;43(2):168-179. doi: 10.1097/WNO.0000000000001786. Epub 2023 Feb 3.

Association between anxiety symptoms and Alzheimer's disease biomarkers in cognitively healthy adults: A systematic review and meta-analysis

Demnitz-King H, Saba L, Lau Y, Munns L, Zabihi S, Schlosser M, Del-Pino-Casado R, Orgeta V, Marchant NL.

J Psychosom Res. 2023 Mar;166:111159. doi: 10.1016/j.jpsychores.2023.111159. Epub 2023 Jan 20.

Brain Gray Matter Volume Mediated the Correlation Between Plasma P-Tau and Cognitive Function of Early Alzheimer's Disease in China: A Cross-Sectional Observational Study

Wan K, Yin W, Tang Y, Zhu W, Wang Z, Zhou X, Zhang W, Zhang C, Yu X, Zhao W, Li C, Zhu X, Sun Z.

J Alzheimers Dis. 2023;92(1):81-93. doi: 10.3233/JAD-221100.

A novel regulator in Alzheimer's disease progression: The astrocyte-derived extracellular vesicles

Li B, Ma Z, Li Z.

Ageing Res Rev. 2023 Apr;86:101871. doi: 10.1016/j.arr.2023.101871. Epub 2023 Feb 2.

Meta-analysis and systematic review of peripheral platelet-associated biomarkers to explore the pathophysiology of alzheimer's disease

Fu J, Lai X, Huang Y, Bao T, Yang J, Chen S, Chen X, Shang H.

BMC Neurol. 2023 Feb 11;23(1):66. doi: 10.1186/s12883-023-03099-5.

Scientific, Ethical, and Practical Considerations for the Testing and Disclosure of Alzheimer Disease Biomarkers

McCusker EA, Loy CT.

Neurology. 2023 May 23;100(21):993-994. doi: 10.1212/WNL.0000000000207199. Epub 2023 Feb 15.

Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging

Hu X, Meier M, Pruessner J.

Brain Behav. 2023 Mar;13(3):e2925. doi: 10.1002/brb3.2925. Epub 2023 Feb 16.

CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab

Nisenbaum L, Martone R, Chen T, Rajagovindan R, Dent G, Beaver J, Rubel C, Racine A, He P, Harrison K, Dean R, Vandijck M, Haeberlein SB.

Alzheimers Dement. 2023 Aug;19(8):3379-3388. doi: 10.1002/alz.12919. Epub 2023 Feb 16.

Biomarkers of diagnosis, prognosis, pathogenesis, response to therapy: Convergence or divergence? Lessons from Alzheimer's disease and synucleinopathies

Sensi SL, Russo M, Tiraboschi P.

Handb Clin Neurol. 2023;192:187-218. doi: 10.1016/B978-0-323-85538-9.00015-8.

Association between primary care electrocardiogram markers and Alzheimer's disease

Isaksen JL, Ghouse J, Skov MW, Olesen MS, Holst AG, Pietersen A, Nielsen JB, Maier A, Graff C, Gerds TA, Frikke-Schmidt R, Kanters JK.

J Neurol Sci. 2023 Apr 15;447:120581. doi: 10.1016/j.jns.2023.120581. Epub 2023 Feb 9.

Metabolic defects shared by Alzheimer's disease and diabetes: A focus on mitochondria

Carvalho C, Moreira PI.

Curr Opin Neurobiol. 2023 Apr;79:102694. doi: 10.1016/j.conb.2023.102694. Epub 2023 Feb 24.

Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease

Rani S, Dhar SB, Khajuria A, Gupta D, Jaiswal PK, Singla N, Kaur M, Singh G, Barnwal RP.

Cell Mol Neurobiol. 2023 Aug;43(6):2491-2523. doi: 10.1007/s10571-023-01330-y. Epub 2023 Feb 27.

Neuropsychiatric Symptoms and Commonly Used Biomarkers of Alzheimer's Disease: A Literature Review from a Machine Learning Perspective

Shah J, Rahman Siddiquee MM, Krell-Roesch J, Syrjanen JA, Kremers WK, Vassilaki M, Forzani E, Wu T, Geda YE.

J Alzheimers Dis. 2023;92(4):1131-1146. doi: 10.3233/JAD-221261.

Advances in sample preparation and HPLC-MS/MS methods for determining amyloid-β peptide in biological samples: a review

de Souza ID, Queiroz MEC.

Anal Bioanal Chem. 2023 Jul;415(18):4003-4021. doi: 10.1007/s00216-023-04631-9. Epub 2023 Mar 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias